Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report sent to investors on Monday. The brokerage issued a hold rating on the medical research company’s stock.

A number of other research analysts also recently issued reports on CTSO. HC Wainwright reiterated a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a research note on Monday, November 11th. EF Hutton Acquisition Co. I raised shares of Cytosorbents to a “strong-buy” rating in a research report on Monday, July 29th.

Cytosorbents Stock Performance

Shares of CTSO opened at $0.93 on Monday. Cytosorbents has a 1 year low of $0.70 and a 1 year high of $2.15. The stock has a market capitalization of $50.85 million, a PE ratio of -2.58 and a beta of 0.56. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.71 and a current ratio of 1.97. The stock has a 50-day simple moving average of $1.12 and a 200-day simple moving average of $1.01.

Institutional Investors Weigh In On Cytosorbents

Several institutional investors have recently added to or reduced their stakes in the business. CM Management LLC increased its stake in Cytosorbents by 3.0% in the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after purchasing an additional 25,000 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after buying an additional 32,415 shares during the last quarter. Atomi Financial Group Inc. purchased a new position in shares of Cytosorbents in the 3rd quarter valued at $51,000. Sargent Investment Group LLC raised its stake in Cytosorbents by 4.9% during the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after acquiring an additional 67,181 shares in the last quarter. Finally, Avenir Corp lifted its position in Cytosorbents by 4.0% in the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock valued at $3,014,000 after acquiring an additional 121,294 shares during the last quarter. Hedge funds and other institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.